Abbott receives u.s. fda clearance for two new over-the-counter continuous glucose monitoring systems

Abbott's consumer biowearable, lingo™, is designed for general consumers who are looking to improve their overall health and wellness libre rio™ is designed for adults with type 2 diabetes who do not use insulin and typically manage their diabetes through lifestyle modifications both products are based on freestyle libre® sensing technology, the world's most widely used1 continuous glucose monitoring (cgm) systems, pioneered by abbott and used by about 6 million people globally2 abbott park, ill., june 10, 2024 /prnewswire/ -- abbott (nyse: abt) today announced u.s. food and drug administration (fda) clearance for two new over-the-counter continuous glucose monitoring (cgm) systems – lingo™ and libre rio™, which are based on abbott's world-leading freestyle libre® continuous glucose monitoring technology1, now used by about 6 million people globally2.
ABT Ratings Summary
ABT Quant Ranking